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Introduction: Atrial synchronous left ventricular (LV) only pacing using two leads and VDD
pacemaker could be a cost effective alternative to conventional cardiac resynchronization
therapy (CRT).
Methods: We implanted right atrial (RA) and LV leads with VDD pulse generator (LV only
pacing) in five carefully screened heart failure patients who could not afford conventional
CRT. All had NYHA class III/IV symptoms despite maximal guideline directed medical
therapy. The sensed atrioventricular delay was programmed to pre-excite the LV and
achieve fusion beat. Response to treatment was assessed at 6 months.
Results: Four patients were males. The mean age was 58 ± 12 years. At follow up, there was
improvement in electrocardiographic, and echocardiographic parameters: Mean QRS
duration decreased from 174 ± 17 msec to 128 ± 10.9 msec (p ¼ 0.009), LV end-diastolic
diameter decreased from 73.2 ± 12 mm to 65.8 ± 9.6 mm (p ¼ 0.026), LV end-systolic
diameter decreased from 65 ± 12 mm to 54 ± 10 mm (p ¼ 0.020). There was a trend to-
wards reduction of LV end-systolic and end-diastolic volumes. LV ejection fraction
improved from 25 ± 6% to 34 ± 6% (p ¼ 0.013) and left atrial dimension reduced from
44 ± 4 mm to 39 ± 5 mm (p ¼ 0.045). All patients improved clinically.
Conclusion: RA-LV pacing using VDD pacemaker is a safe and effective technique of CRT.
This may be a cost effective alternative to conventional CRT for patients in developing
countries.
Copyright © 2014, Cardiological Society of India. All rights reserved.RT, Cardiac resynchronization therapy; GDMT, guideline directed medical therapy.
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Cardiac resynchronization therapy (CRT) with biventricular
(BiV) pacing has emerged as an important treatment option in
patients with heart failure refractory to guideline directed
medical therapy (GDMT).1 Though found to be very effective in
such patients, CRT is underutilized in a developing country
like India, due to its high cost. There is no device database/
registry in India from where data about CRT usage in the
country could be derived. In our centre, only about one fifth of
heart failure patients with class I indication undergo CRT
implantation (unpublished data).
Univentricular pacing i.e., pacing the right atrium and left
ventricle (LV only pacing) instead of both right and left ven-
tricles has been explored as an alternate treatment modality
to achieve CRT in many studies.2e11 LV only pacing has
emerged on the knowledge that restoration of intraventricular
dysynchrony is sufficient to restore LV synchrony. This
argument makes RV lead pacement redundant in certain
conditions of heart failure.7,8,12 Trials evaluating LV only
pacing used CRT pacemaker system. These studies postulated
that LV only pacing can be offered to patients at a substan-
tially reduced cost compared to BiV pacing.3,13 We offered LV
only pacing using VDD pacemaker system to patients who
could not afford conventional BiV pacing. We report here our
experience in using VDD pacemaker system for CRT.2. Methods
This is a retrospective analysis of patients in whom CRT was
performed using VDD pulse generator which senses RA and
paces only LV. We offered this treatment to patients who had
symptoms of heart failure despite GDMT and could not afford
conventional CRT. The procedure was performed on patients
who had the following: NYHA functional class III or ambula-
tory class IV, sinus rhythm, LBBB, QRS duration of 150 ms,
LVEF 35%, left ventricular end-diastolic diameter
(LVEDD) 55 mm and on continuous GDMT for at least three
months prior to procedure. We excluded patients who had
sinus bradycardia, atrial fibrillation, atrioventricular conduc-
tion disease and renal failure (serum creatinine >1.5 mg/dl).
Patients with hypertrophic or restrictive cardiomyopathy,
suspected acute myocarditis, valvular heart disease, acute















1 68 F IV 180 70 67 3
2 40 M IV 170 73 64 1
3 68 M III 160 73 66 1
4 62 M IV 160 92 81 3
5 54 M IV 200 58 47 1
LVEDD indicates left ventricular end-diastolic diameter; LVESD, left ven
volume; LVESV, left ventricular end-systolic volume; EF, ejection fractionrevascularization in the past three months were not consid-
ered for the procedure.
2.1. Pacemaker implantation and programming
We used standard VDD pacemakers to synchronize RA and
LV. The RA and LV leads were positioned transvenously
through the left subclavian vein using an extrathoracic
approach. A coronary sinus venogram in levophase was ob-
tained prior to LV lead placement. The LV lead was positioned
according to standard protocol avoiding the great and middle
cardiac veins. We preferred the lateral wall for LV lead
placement, where the local ventricular activation was at the
terminal portion of the QRS (latest site of LV depolarisation).
The sensed AV delay was programmed to pre-excite LV and
allow the native conduction to depolarize RV. The pro-
grammed AV delay and LV lead thresholds for individual pa-
tients are given in Table 1. Patientswere discharged between 3
and 5 days after the implantation with an advice to follow
strict medical therapy for heart failure.
2.2. Follow up
Patients were periodically followed up in the device clinic.
Response to therapy was assessed six months post implan-
tation using clinical and echocardiographic parameters:
NYHA functional class, LV dimensions and volumes, ejection
fraction (EF), LA dimension and mitral regurgitation (MR) jet
area.
2.3. Echocardiographic methods
M-mode measurements of the two-dimensional parasternal
long axis view was used for assessment of LV dimensions. LV
volumes and LVEF were calculated using Simpson's biplane
method. LA dimension was measured in parasternal long axis
view and MR jet area by vena contracta method.3. Results
A total of seven patients underwent CRT with LV only pacing
between October 2009 and January 2013. Two patients had
their follow up assessments done elsewhere. Hence, results of
only five patients are shown. The mean age of five patients














23 254 42 4.8 120 1.5
66 126 47 14.6 140 1.0
65 110 40 2.1 160 1.5
90 310 44 15.7 120 2
93 115 49 1.1 140 1.5
tricular end-systolic diameter; LVEDV, left ventricular end-diastolic
; LAd, left atrial diameter; MR, mitral regurgitation.
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dilated cardiomyopathy and one, ischaemic cardiomyopathy.
Baseline characteristics and pacing parameters of individual
patients are shown in Table 1.
3.1. Response to LV only pacing
All patients had an improvement in clinical status as assessed
by NYHA functional class. There was good improvement in all
end points assessed (Table 2) with significant improvement
seen in QRSd, LV dimensions and EF (Fig. 1). Diuretic
requirement reduced substantially in all patients. Device
interrogation did not show any atrial or ventricular
arrhythmia. There was no mortality.Fig. 1 e Change in left ventricular ejection fraction in
individual patients six months post RA-LV only pacing.
The figure shows change in left ventricular ejection
fraction as assessed by echocardiography in all five
patients who underwent RA-LV only pacing from baseline
to six months following procedure.4. Discussion
To the best of our knowledge, this is the first time a VDD
pacemaker system has been used for cardiac resynchroniza-
tion. This method was beneficial in significantly reducing the
costs for the patients and also providing clinical improve-
ment. The LV pacing used in this series of five patients
resulted in LV reverse remodelling thereby improving the
clinical status of all patients.
The safety and efficacy of LV only pacing have been
explored in several studies6,8,9,11,14e18 and found to be com-
parable with the time tested BiV pacing.
4.1. Haemodynamic effects
Both LV only and BiV pacing have demonstrated similar he-
modynamic results during acute studies with favourable
changes in pulmonary artery pressures, cardiac output, sys-
temic blood pressure and dp/dt.6,14,15 Comparable benefits
between LV only pacing and BiV pacing have been demon-
strated in mid-term8,9 and long-term studies as well.16 In a
study by Auricchio et al,17 three months of active LV pacingTable 2 e Comparison of the mean effect of CRT with RA-
LV only pacing on electrographic and echocardiographic








QRSd (msec) 174 ± 16.7 128 ± 10.9 0.009
LVESD (mm) 65 ± 12.1 53.8 ± 9.8 0.026
LVEDD (mm) 73.2 ± 12.2 65.8 ± 9.6 0.020
ESV (ml) 183 ± 92.6 152.6 ± 72.9 0.103
EDV (ml) 247.4 ± 102 242.8 ± 117 0.862
LVEF (%) 24.6 ± 6.1 33.6 ± 5.5 0.013
LA
dimension (mm)
44.4 ± 3.6 38.8 ± 5.02 0.045
MR jet area (cm2) 7.6 ± 5.9 2.2 ± 1.7 0.076
LVEDD indicates left ventricular end-diastolic diameter; LVESD, left
ventricular end-systolic diameter; ESV, End-systolic volume; EDV,
Left ventricular end-diastolic volume; LVEF, Left ventricular ejec-
tion fraction; LA, left atrium; MR, mitral regurgitation. p value <0.05
was considered statistically significant.was compared to three months of inactive pacing in patients
with severe congestive heart failure and wide QRS duration.
During active LV pacing, there was a significant increase in
peak VO2 and in 6 min walk distance. Patients with QRS
duration >150 ms had more pronounced benefit than with a
lesser QRS duration.
4.2. Clinical benefits
LV only pacing showed similar improvement to BIV in terms of
functional class, quality of life score and exercise tolerance as
observed in a study with a cross-over design by Auricchio
et al.18 The study compared two active periods of four weeks
each of LV only and BIV pacing. In a follow up study (12
months) with exclusive LV only pacing by Blanc et al19 in se-
vere congestive heart failure, sinus rhythm and LBBB, there
was significant improvement in NYHA functional class, ex-
ercise tolerance and blood levels of norepinephrine. In our
patients of CRT with LV pacing using VDD pulse generator,
there was improvement in clinical and echocardiographic
parameters in all the five patients.
GREATER EARTH,11 a double-blind, cross-over study
showed similar benefits between LV only pacing to BiV in
terms of exercise capacity, LV function and volume, and
circulating levels of N-terminal natriuretic peptide. In this
study, among the clinical non-responders to BiV, 21%
improved and among the non-responders as assessed by
echocardiography, 17% responded favourably when crossed
over to LV only pacing.
Though many studies have demonstrated the non-
inferiority of LV only pacing to BiV, the acceptance of this
mode of pacing therapy in clinical practice is very low. From a
clinical perspective, the 2013 ESC guidelines on pacing20 rec-
ommends LV only pacing in non-pacemaker dependent pa-
tients “to decrease the cost and complexity of the procedure
Table 3 e Comparative assessment of cost involvement
between atrial synchronized biventricular cardiac





Device with lead system Rs. 347,000 Rs. 175,000
Procedure Rs. 80,000 Rs. 30,000
Hospitalization Rs. 30,000 Rs. 15,000
Total cost Rs. 457,000 Rs. 220,000
The cost mentioned in the table is the approximate cost offered to
patients in our institution.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 1 2e6 1 6 615and increase the longevity of the device”. As placement of LV
lead compared to RV consumes more time and needs more
expertise, the benefits from reducing time or technical
complexity may not be significant by employing LV only
pacing but, there is definitely a significant cost benefit
involved.
4.3. Cost effectiveness
In our series, all five patients were in advanced heart failure
with NYHA class III-IV symptoms and re-modelled LV
despite GDMT. They would have continued to deteriorate if
CRT was not offered to them. Hence, we offered CRT using
VDD pacemaker system. Employing LV only pacing using
VDD pulse generator system has definite cost benefit over
BiV (Table 3).
This form of resynchronization will be useful in patients
with good AV nodal conduction and who are unlikely to
develop an AV block in future. Patients having sinus node
dysfunction with indication for atrial pacing and those who
require a concomitant intracardiac defibrillator are not ideal
candidates for LV only pacing.
4.4. Limitations
Ours is a non-randomized study with no control arm. In
addition, the procedure was offered on compassionate
grounds to a selected subset of patients with advanced heart
failure. Our inclusion criteria were stringent and included
patients who were most likely to benefit from BiV as seen in
many randomized studies. This might explain the high
responder rate observed in our patients. Therefore, the
applicability of LV only pacing in other conditions could not be
commented based on our experience. Further long-term
follow up studies are needed to identify the suitable popula-
tion that might achieve maximum benefit from LV pacing
using VDD pacing system.5. Conclusion
RA-LV pacing using VDD pacemaker is a safe and effective
technique of CRT. This may be a cost effective alternative
to conventional CRT for patients in developing countries.
Large randomized studies are needed to confirm our
observations.Conflicts of interest
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